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Review
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Abstract: The ecology of infectious disease in wildlife has become a pivotal theme in animal and public health.
Studies of infectious disease ecology rely on robust surveillance of pathogens in reservoir hosts, often based on
serology, which is the detection of specific antibodies in the blood and is used to infer infection history.
However, serological data can be inaccurate for inference to infection history for a variety of reasons. Two
major aspects in any serological test can substantially impact results and interpretation of antibody prevalence
data: cross-reactivity and cut-off thresholds used to discriminate positive and negative reactions. Given the
ubiquitous use of serology as a tool for surveillance and epidemiological modeling of wildlife diseases, it is
imperative to consider the strengths and limitations of serological test methodologies and interpretation of
results, particularly when using data that may affect management and policy for the prevention and control of
infectious diseases in wildlife. Greater consideration of population age structure and cohort representation,
serological test suitability and standardized sample collection protocols can ensure that reliable data are
obtained for downstream modeling applications to characterize, and evaluate interventions for, wildlife disease
systems.
Keywords: antibody prevalence, epidemiological models, immunity, surveillance, wildlife disease
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INTRODUCTION
Globally, emerging infectious diseases represent a threat to
human and animal health (Daszak et al. 2000; Woolhouse
et al. 2008). Most emerging diseases originate from wildlife
(Taylor et al. 2001), where they may infect multiple animal
hosts (Haydon et al. 2002). Understanding disease emergence requires consideration of the pathogen, animal hosts
that are naturally infected by the pathogen and the ecological
interactions which facilitate pathogen perpetuation in nature (Childs et al. 2007). The One Health concept recognizes
that human, domestic animal, and wildlife health are interconnected and should be considered within an ecosystem
context (Kaplan et al. 2009), while promoting collaboration
between microbiologists, ecologists, epidemiologists, physicians, veterinarians, and modelers in the development of
conceptual and mathematical system models. Models can
guide appropriate disease surveillance, prevention, and
control strategies (Fooks 2007; Zinsstag et al. 2009, 2011).
Communication between these traditionally independent
disciplines relies on a mutual conceptual understanding of
disease surveillance methods and precise interpretation of
the data generated. Subsequent data use in predictive models
must recognize the strengths and limitations of the techniques utilized (Table 1). This paper presents concepts and
examples that may appear obvious to immunologists and
microbiologists, yet may be unknown, or overlooked by,
ecologists, modelers, and policy makers.
The measurement of antibodies in blood is a critical
disease surveillance tool because antibodies are typically
easier to detect and persist longer than the inciting infectious
agents. Serological assays detect antibodies induced by
infection or vaccination, and provide evidence of past
exposure to a pathogen. Although ecologists, modelers and
policy makers may receive little training in immunology or
the technical aspects of measuring host immune response to
infection, they often must rely on serological data for inference to pathogen force of infection and transmission rates, as
well as to parameterize dynamic disease models. Here we
review the role of antibody assays and the interpretation of
results in wildlife disease investigations, for an audience with
little training in immunology or laboratory diagnostics. We
discuss common factors that lead to misinterpretation of
serological data, which primarily result from a lack of
understanding about host immune response to infection and
variation in test sensitivity and specificity. We address issues
relating to the interpretation of antibody prevalence data
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from wildlife, and provide recommendations to guide study
design and inference using serologic data (Table 2).

APPROACHES
INFECTIONS

TO

STUDYING WILDLIFE

Incidence and prevalence are the most frequently used
measures to describe the epidemiology of infection in natural
populations. Incidence is the number of new infections in a
population-at-risk over time. Prevalence can be described as
point or period, with the former describing the proportion of
infected animals in a population at any particular moment,
and the latter describing the proportion of infected animals
in a population over a designated period of time (e.g., season). Antibody prevalence (i.e., seroprevalence) describes
the proportion of individuals within a population that
demonstrate pathogen-specific antibodies in the serum.
Longitudinal or cross-sectional sampling strategies gather
data on incidence and prevalence to infer temporal or spatial
infection dynamics in wildlife populations.
Longitudinal studies repeat sampling of individuals,
social groups, or populations, to detect changes in antibody
prevalence over time, and may be used to estimate infection
incidence if the sample size is large enough to detect antibody
seroconversion events in the population (Hazel et al. 2000).
Re-sampling individual wild animals, however, is often
logistically difficult, therefore where it is possible to determine age in a species, age-structured antibody prevalence
data may be utilized to gain insight into pathogen transmission processes (Farrington et al. 2001). However, insights
can be limited by available knowledge regarding individual
serological outcomes to infection (Evans 1976), including
the: probability that an infected individual will seroconvert;
incubation period and case fatality rate of infected individuals; duration of the antibody response to infection; and
relationship between antibody status and resistance to
pathogen infection. Often, few data exist regarding these
fundamental questions and models generated from antibody
prevalence data should recognize such uncertainties.
Cross-sectional studies focus on the social group, population, or species and, in contrast to longitudinal studies,
provide snapshots on current or past infection prevalence
rather than incidence. Antibody prevalence is only equivalent
to infection incidence when the duration of tested antibody is
orders of magnitude shorter than life-span of the host (e.g.,
IgM responses). Cross-sectional studies can document evi-

Correct interpretation
Different classes of antibody and different types
(e.g. binding or neutralizing) have very different dynamics and are not directly comparable
in any respect.

Cross-reactivity must be taken into consideration, particularly in systems where circulating
pathogen diversity has been poorly characterized.
An antibody positive result merely implies previous exposure to antigen, without indication
of the timing of infection. When IgM antibody
activity can be demonstrated, infection may be
active or very recent.

The relationship between immunity and infection
resistance depends on the type of antibody
detected (e.g., binding or neutralizing) and the
disease system. Generally speaking, detectable
antibody does not indicate protection.
Validation should be species, and ideally population, specific.

All antibodies are equal

Finding antibodies to one virus provides specific
evidence of prior exposure with that virus

Antibody positive animals are currently infected

Antibody positive animals are protected against
re-infection

A well validated test in one species can also be
used to directly infer antibody status in another
species

IgM responses are much shorter lived than IgG
responses, and are induced at different stages of
infection. For infections of mucosal surfaces,
IgA responses form an important line of defense.
Neutralizing antibodies imply functional significance against pathogen infection, whereas the
precise activities of binding antibodies may not
be well characterized with regard to host
infection.
Excellent examples are illustrated by Horton et al
(2010) and Mansfield et al (2011). Antibodies
may cross-react and can produce spurious
positive results, particularly against related
viruses.
In some disease systems, such as hantaviruses, an
antibody positive animal can indicate an infected status.
Bats may maintain lyssavirus neutralizing antibodies from months to years with no active
infection (Shankar et al. 2004; Kuzmin et al.
2008).
Measles antibodies generally confer life-long
resistance to infection.
With influenza, antibodies are frequently crossreactive to circulating strains, yet are not necessarily protective against infection with those
strains.
No exceptions to this rule exist.

Examples and counter-examples

Common Misinterpretations of the Meaning of Antibody Positive and Negative Animals in Wildlife Disease Investigations.

Misinterpretation

Table 1.
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Interpretation of antibody testing results is the
same in all populations

All tests are highly specific (accurately able to
identify negative results and avoid false positives) and highly sensitive (accurately able to
identify positive results and avoid false negatives).

The ability to detect true positives (i.e., positive
predictive value-PPV) for a test in a given
population depends on the prevalence of
antibody or infection in that population.
Whenever possible, the specificity, sensitivity
and PPV of a test should be evaluated using a
collection of reference samples that mirror the
suspected prevalence in the wildlife population.

There is no perfect cut-off for any system, and a
cut-off that performs adequately in one species
or population may not be relevant for another
species or population. Proper validation should
occur for every intended use of an assay,
including relevant populations of interest.
Properly validated assays by definition should be
reproducible across laboratories; however,
within- and between-laboratory variation exists. Different cut-offs, quality assurance, standardization (e.g., antigens, cell lines and
control analytes used), and specific methodologies (e.g., protocols, reagents, equipment) are
all sources of test variation.
False negatives and positives do occur and few
assays have been properly validated for use
with any of the diversity of wildlife species.

There is a clear and correct cut-off value and
distinction between positive and negative
individuals

An antibody titer reported from one lab is
equivalent to a titer from another lab

Correct interpretation

continued

Misinterpretation

Table 1.

Low specificity: Horton et al (2010) quantified
cross-reactivity between lyssaviruses. Infection
with one lyssavirus can induce antibodies that
react to others.
Low sensitivity: Turmelle et al (2010b) show that
neutralizing antibodies against rabies virus may
be undetected in bats despite prior exposure
and demonstrated immunity to infection.
In populations where antibody and/or infection
prevalence is low, positive results are more
likely to be false positives than in populations
where prevalence is high, driven by test specificity. If infection is common and test sensitivity low, then negative results are more likely
to be false.

In some cases, an antibody assay may be used to
diagnose prior infection, whereas other uses
may involve defining standards of adequate
immunity following vaccination. Different intended uses of an antibody assay may lead to
different performance cut-offs.
One of the few international systems where attempts have been made successfully to ensure
between lab standardization is for rabies virus
serological assays (Robardet et al. 2011).
The area where there has probably been most
work is with influenza, where standardization
is unreliable (Wood et al. 1994).

Examples and counter-examples

Serologic Testing for Wildlife Diseases

301

Correct interpretation
It cannot be easily determined whether antibodies
are maternally-derived (passive) or represent
an active response to infection.

The duration of the antibody response may vary
by host-pathogen system, but antibody titers
generally wane over time following infection.
High infection-associated mortality complicates detection of antibody-positive animals.
Infection dynamics may fluctuate seasonally or
annually.
In the majority of cases this is not possible, but in
specific situations vaccines or serological tests
have been designed to differentiate immunization from infection.

Antibody responses are highly variable between
individuals, dynamic over time and vary significantly between primary and secondary
infections (where anamnestic responses occur).

Antibodies in young animals indicate pathogen
exposure

Seronegative population equals no infection, and
seronegative individuals are naı̈ve.

Serological tests can differentiate vaccinated and
infected individuals

You can infer timing of infection from magnitude
of antibody titer

continued

Misinterpretation

Table 1.

If IgM antibodies are reliably demonstrated, then
infection may have occurred in young animals.
Detection of antibodies in a young animal is
problematic to interpret and best accomplished
by the sampling of known dam-offspring pairs,
with differentiation of IgM and IgG antibody
classes where possible.
Turmelle et al (2010b) clearly show that the
induction of antibodies to rabies virus in bats
may depend on the viral infection dose and
antibody levels may drop below detection levels
in animals that seroconvert following infection.
Rabies virus and herpesviruses may evade host
immune detection, and thus seronegative animals may be infected.
Antibodies to non-structural proteins (NSPs) are
not usually elicited following vaccination with
inactivated products. DIVA (differentiating
infected from vaccinated animals) vaccines rely
on detection of antibodies to NSPs, but such
assays are generally unavailable.
Validated assays against IgM antibody can be
used to infer recent timing, but this is unusual.
Host or environment specific factors can also
limit the strength of an antibody response,
precluding reliance on magnitude of titer to
infer timing or dose of infection.

Examples and counter-examples
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Table 2.
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Recommendations for the Use of Serologic Testing for Inference to Wildlife Disease Monitoring or Surveillance.

1. Investigations of wildlife disease should be developed from a conceptual, and ideally quantitative, model of the study system. Early and
continual communication with disease experts and diagnosticians in the specific field is imperative for consideration of the optimal
test(s) employed, along with associated strengths and limitations for the purpose of study.
2. Full biological information from sampled animals (i.e., locality, species, age, sex, reproductive status) should be collected and reported, and
ideally, longitudinal investigations should be conducted rather than cross-sectional studies, with an emphasis on age-structured sampling.
3. Extreme care should be taken to optimize sample quality prior to testing, including sterile technique, maintenance of proper cold chain
and storing multiple aliquots of a sample. Similarly, although difficult in many wildlife studies, all samples collected for a study should
be handled in an identical manner across study locations and years.
4. Whenever possible, all samples should be processed by the same operator using identical positive and negative controls. Otherwise, all
samples should be tested within the same test run.
5. Full reporting of test methodology and results are critical to allow comparisons with other studies, including a description of precise
protocols or modifications employed, including cut-offs, controls and confidence intervals for antibody prevalence estimates.
6. Where possible, results from one type of assay should be confirmed using an alternative test.
7. In the absence of demonstrating that a specific pathogen strain used in a test also occurs in the population sampled, or in systems where
cross-reactivity has been demonstrated, consider the possibility of cross-reactivity with other pathogens or strains of the pathogen of
interest.
8. Caution in interpretation should be exercised when antibody titers of individuals in a population are very low.

dence for circulation of a pathogen within a group, population, geographic area, or species; for example, during
exploratory or outbreak investigations when the infection
status of a population, or the natural host range of a pathogen,
is unknown (Swanepoel et al. 2007; Lembo et al. 2011). A
major limitation of single cross-sectional studies is that they
do not provide information on infection dynamics. However,
cross-sectional antibody prevalence data may still be useful for
disease ecology studies, and in some cases more useful than
infection prevalence data (Heisey et al. 2006). For example,
antibodies typically persist longer than antigen, and hence are
more likely to be detected within a population ‘snapshot’.
Repeated cross-sectional surveys that incorporate age-structured sampling may permit inference into temporal infection
dynamics of wildlife (Plowright et al. 2008; Hayman et al.
2012). Cross-sectional surveys can also be used to evaluate
spillover risk from wildlife populations. For example, crosssectional surveys of antibodies to Brucella abortus in elk or to
pseudorabies virus in wild swine inform managers where
spillover to livestock is most likely to occur, and hence where
to target management (Cross et al. 2007; Pannwitz et al. 2011).
Serology has also been used to evaluate risk of spillover from
domestic animals to wildlife, as with canine distemper virus
transmission from domestic dogs to Serengeti carnivores
(Alexander and Appel 1994; Cleaveland et al. 2000).
Cross-sectional antibody data are important in planning and evaluating wildlife disease management strategies. For example, vaccination against rabies virus (RABV)
is undertaken annually in North America and Europe

through the use of recombinant or modified live virus
vaccines, enclosed in a bait for oral consumption by target
wildlife (Rupprecht et al. 2008). Cross-sectional surveys
are used to determine the pre-intervention spatial distribution of immunity so that vaccine baits can be optimally
distributed (Vos 2003), and post-vaccination herd
immunity for inference to bait uptake and infection
resistance (Sidwa et al. 2005). RABV vaccination and
modeling of immunity were management strategies also
used to prevent the extinction of the Ethiopian wolf
(Canis simiensis) (Haydon et al. 2006; Knobel et al. 2008).
Another example involves management of bovine tuberculosis (Mycobacterium bovis) spillover to cattle through
Bacillus Calmette–Guérin (BCG) vaccination of a wildlife
reservoir, the European badger (Meles meles), in Great
Britain (Chambers et al. 2011). Discrimination of infected
versus vaccinated badgers was possible in this study
(Greenwald et al. 2003), though it is typically not possible
with antibody prevalence data.
A valuable step in designing ecological wildlife disease
investigation involves the development of a conceptual, and
ideally quantitative and predictive epidemiological model
of the system. Early communication and collaborative
model development ensure that appropriate data will be
collected to inform a predictive model of the system (Restif
et al. 2012) (Table 2). Traditional epidemiological models
identify the basic compartments which formally define
cohorts of susceptible, exposed, infected and (perhaps)
recovered or immune individuals (i.e., SEIR), and the
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interactions among these cohorts which facilitate the
invasion and maintenance of a pathogen in animal or plant
populations (Anderson and May 1979, 1986). To parameterize these models, knowledge of the actual infection status
of animals, and how this changes over time, is required.
Acquiring these data could involve the lethal sampling of
large numbers of animals, particularly if infection incidence
is low. As this usually is neither feasible nor ethical, antibody data are used as a proxy for prevalence of infection.
Serological data may be more useful than infection
prevalence data in determining the force of infection—the
rate at which susceptible individuals become infected and
the foundation for estimating transmission rates (Heisey
et al. 2006). If antibody loss is slow and disease-induced
mortality is well understood (Heisey et al. 2006, 2010),
serology as an indicator of past infection may be more easily
interpreted than prevalence data. For example, a low prevalence could be generated by a high force of infection and fast
recovery rate, or a low force of infection and low recovery
rate—problems avoided with serology if titers are long-lived.
Factors associated with the infection process, such as
pathogen dose, variant and route of inoculation, can all impact
the induction of a host antibody response to infection. While
detection of antigen-specific antibodies usually indicates prior
exposure to a pathogen, negative test results do not necessarily
rule out prior exposure (Turmelle et al. 2010b). Antibodypositive animals are not necessarily infected animals, as one
study demonstrated during a survey for Puumala virus in wild
bank voles (Clethrionomys glareolus) (Alexeyev et al. 1998). It
is often assumed that the immune class (R) of animals in SEIR
models is equivalent to seropositive animals, when in fact
antibodies may not be a reliable indicator of infection resistance (Raberg et al. 2009). In addition, variation in the sensitivity of antibody detection methods may exist (Cleaveland
et al. 1999; Chambers et al. 2002; Troyer et al. 2005), with
apparent trade-offs between sensitivity (ability to identify
positive results and avoid false negatives) and specificity
(ability to identify negative results and avoid false positives)
for any assay. However, application of novel modeling
methodologies, such as site-occupancy models, may tolerate
imperfect detection probabilities based on serosurveys and
other diagnostic techniques (Lachish et al. 2012).

DETECTING INFECTIONS

IN

WILDLIFE

The objective of disease surveillance systems is to track the
incidence and prevalence of a specific pathogen infection in

populations of interest. Several diagnostic techniques can
obtain such data, each having its own strengths and limitations
(OIE 2010). Pathogen isolation (e.g., using cell culture or
animal models) permits identification and characterization of
the disease agent, and enables animal infection experiments
which are necessary to fulfill Koch’s postulates (Evans 1976)
and characterize host pathogenesis. Pathogen isolation also
permits a greater epidemiological understanding of the circulating pathogen diversity within and among reservoir and
incidental hosts (Streicker et al. 2010). However, pathogen
isolation from wildlife can be challenging even under ideal
laboratory conditions. Infection burdens may be low, as observed with henipavirus infections in bats (Middleton et al.
2007; Halpin et al. 2011), or the pathogen may be sequestered
in organs, thereby requiring lethal sampling, as with brucellosis in bison (Bison bison) and elk (Cervus elaphus) (Baldwin
and Roop 2002) or classical swine fever in wild swine (Sus
scrofa) (Kaden et al. 2006). Some infections may be latent, i.e.,
dormant in the body but with potential for reactivation, as has
been observed with pseudorabies in wild swine (Wittmann
and Rziha 1989). Often, animal infectious periods are short, as
seen with RABV and canine distemper virus (Deem et al. 2000;
Hampson et al. 2009), with few animals infected at any given
time, thereby requiring very large sample sizes to detect
infection. Finally, the handling and isolation of some pathogens requires high containment facilities only found in specialist laboratories. These factors might make obtaining
isolates from wildlife impractical in many cases.
Direct pathogen detection tests, other than isolation,
such as antigen-detection assays and molecular diagnostic
tools (e.g., the polymerase chain reaction—PCR), can be
used to detect evidence of active or latent infection. These
methods share many of the limitations of pathogen isolation:
unless a pathogen is circulating in blood, excreted in urine or
feces, or colonizing an accessible mucosal surface or superficial lymph node, lethal sampling of wildlife will be required. Despite this, detection of host pathogen excretion via
accessible pathways (e.g., blood or mucosal surfaces) can
provide meaningful insights for parameterizing transmission probabilities and rates, although several studies also
recognized that pathogen excretion may be intermittent
among infected animals (Baer and Bales 1967; Chambers
et al. 2002; Middleton et al. 2007), potentially limiting
inference from cross-sectional snapshots. However, sample
integrity is a key factor for field studies and maximizing the
probability of successful pathogen isolation or detection
often requires cold-chain or laboratory capacity that is difficult in a field setting, especially in remote geographic areas.

Serologic Testing for Wildlife Diseases

Given some limitations of pathogen isolation and antigen
detection methods, antibody prevalence data are often used to
elucidate infection dynamics in animal populations. The
presence of specific antibody, however, only demonstrates
past exposure to an antigen, while typically providing no
information about the timing, intensity or frequency of
infection. At a population level, antibody prevalence data
provide information about the cumulative exposure history of
the population, but not necessarily infection status. Antibody
prevalence does not change quickly in response to changes in
infection incidence, particularly when antibodies persist for
long periods and host population turnover is slow. Some
pathogens have evolved strategies to circumvent detection by
the host immune system (e.g., lyssaviruses and herpesviruses)
(Aleman et al. 2001; Faber et al. 2002; Wang et al. 2005), thus
complicating the reliance on serological techniques to track
infection dynamics. Notable testing limitations with serological techniques include cross-reactivity, poor accuracy, and
undefined or non-standardized cut-off values to interpret an
antibody-positive result. Because presence of antibody may
not confer infection resistance, it is critical to explore the
significance of an antibody-positive status in the context of a
controlled infection process, using in vitro and in vivo models.
However, with careful study design and interpretation (Table 2), antibody prevalence can be an invaluable tool for
understanding the ecology of disease dynamics, even in
poorly-understood systems such as wildlife populations.

OPTIMAL TEST SELECTION
INTERPRETATION

AND

The two main classes of antibody targeted in serological
testing are IgM and IgG, where IgM is secreted first in response
to pathogen infection yet is usually short-lived, whereas IgG is
secreted later and persists longer in the circulation. Serological
assays typically detect either binding (BAb) or neutralizing
antibodies (NAb), and the type of test determines the type of
antibodies that are detected and the subsequent inference that
is possible from such data (Table 3).
Regardless of the assay selected, proper test validation,
and stringent laboratory quality control standards are key to
reliable collection and interpretation of antibody prevalence
data (OIE 2010). Standard practice requires that appropriate positive and negative controls (ideally, relevant to the
host population sampled) be employed in every test. Although laboratory strains of a pathogen may be employed
for assay standardization, a field-derived strain of the
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pathogen may be more appropriate for certain systems or
questions. Where pathogen diversity within a population,
species or community is high, e.g. paramyxoviruses among
bats (Drexler et al. 2012), it may be desirable to include
multiple pathogen strains in serological tests (Kuzmin et al.
2011). The recent development of pathogen pseudotypes for
serologic testing can facilitate testing of diverse pathogen
repertoires using small sample volumes while minimizing
biohazards (Temperton et al. 2005; Wright et al. 2008).
Cross-reactivity of antibodies to multiple pathogens has
been important in vaccine development, but can also limit
the interpretation of antibody prevalence data (Weyer et al.
2008; Horton et al. 2010; Mansfield et al. 2011). Cross
reactivity can pose particular challenges in disease investigations of wildlife, as there is often no prior characterization
of circulating pathogen diversity or cross-reactivity within
and among populations. For example, antisera raised
against one flavivirus can cross-react with other flaviviruses
(Mansfield et al. 2011), but cross-reactivity within and between flavivirus serocomplexes has been inconsistent (Calisher et al. 1989a). One consequence of flavivirus crossreactivity is reduced specificity in serological assays (Hirota
et al. 2010), which led to the early misdiagnosis of the North
American West Nile Virus epidemic as St. Louis Encephalitis in New York City (Lanciotti et al. 1999; WHO 1999).
However, the idea of cross-reactivity limiting the specificity
of serological assays extends to a variety of systems, as
demonstrated among rhabdoviruses (Calisher et al. 1989b).
Evaluation of test repeatability and robustness is necessary
for sound interpretation of serological test results, particularly
for longitudinal studies. Inter-laboratory variation is a wellrecognized issue for all pathogen testing, but some assays,
particularly virus neutralization tests (VNTs), are prone to
variation even within the same laboratory. This is because they
are biologically dynamic tests, relying on consistent replication
of live virus populations in cell culture. The NAb titer of a single
control serum tested against a standard laboratory strain of
RABV in a closely controlled test can vary by more than twofold (Figure 1). The precise quantity of virus used in neutralization assays affects estimated antibody titers. To counter this,
acceptable standards of variation must be developed with regard to positive and negative controls, with any test results that
do not fall within strict and pre-determined values being discarded. Although frequently not performed, longitudinal
samples from individuals should be tested in the same assay at
the same time, rather than in consecutive assays.
Within and between assay—and between laboratory—
variation has been carefully evaluated for serological assays
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Figure 1. The correlation between results obtained from testing one
control serum against one virus in multiple assays (n = 3167) in a
rabies virus neutralization test using a single challenge virus standard
(CVS). A linear regression model (solid line, R2 = 0.16, P < <0.01)
shows a 0.18 log2 reduction in serum titer for every twofold increase
in virus titer and substantial variance in serum titer (standard
deviation 0.42 log2). Virus titer is measured for each test, and results
are discarded if the infectious dose is outside pre-determined limits
(4.32–8.23 log2 median tissue culture infective dose–TCID50).

in influenza, particularly in humans in relation to vaccination (Wood et al. 1994), but also for horses (Mumford
2000). When considering the two most commonly used
and well-controlled serological assays available for human
influenza, hemagglutination inhibition (HI) and single radial hemolysis (SRH) assays, Wood et al (1994) reported
that although each technique was reproducible within
laboratories, variability between laboratories was higher for
HI (maximum variability 32-fold; geometric coefficient of
variation, GCV, 112%) than for SRH (maximum variability
3.8-fold; GCV 57%). The potential for such variation is
usually overlooked when interpreting serological data.
To determine population antibody prevalence and to
evaluate the sensitivity and specificity of a test, values obtained with a given test sample are evaluated against a
reference cut-off value, meaning that all values below the
cut-off are considered antibody-negative and all values
above the cut-off value are considered antibody-positive.
Standard cut-off values are often not known, usually due to
a lack of well-characterized reference samples from target
wildlife populations. Modification of a cut-off value has a
direct impact on the sensitivity and specificity of the

serological assay—and hence estimated antibody prevalence. For this reason, it can be difficult to compare serological results across studies, particularly as cut-off values
usually are not standardized between laboratories and because many publications report only proportional antibody
prevalence rather than individual titers. Comparisons are
more difficult when pathogen strains or antigens used in a
serological test vary across studies. Estimating antibody
prevalence is most problematic with regards to the evaluation of low-titer individuals and their proportion within a
population, such that reporting results as quantitative
values may be more informative (Peel et al. 2012).
An example of how different criteria can affect interpretation of results involves the testing of 166 European bats
for European bat lyssavirus (EBLV) NAb. Using the same
cut-off threshold for a positive response (i.e., a 1:27 dilution), but a different level of virus neutralization (100%
versus 50% reduction in fluorescing fields) can lead to
variation in NAb prevalence estimates, ranging from 0.6%
(CI 0.0-3.3) under more stringent criteria (i.e., 100% neutralization) to 4.8% (CI 2.1-9.3) under less stringent criteria
(i.e., 50% neutralization) (AVHLA, unpublished data).
Similarly, in a study of RABV NAb among sera collected
over two years from 1,058 bats in the United States, an
increase in test cut-off threshold from 0.06 international
units per ml (IU/ml) to 0.1 IU/ml led to a reduction in
RABV NAb seroprevalence from 38% (CI 35-41) to 28% (CI
25-31) (CDC, unpublished data). While variation in testing
conditions can be accounted for by using reference positive
control sera of known potency, the above examples highlight the difficulties in running longitudinal samples across
different years or operators and demonstrate that different
estimates of antibody prevalence from the same samples are
possible. Instances where positive control sera are not included or reported are especially troubling, and make it
difficult to control for test variation across operators or
laboratories. Efforts must be made to standardize methods
and result interpretation and reporting across laboratories.

SEROLOGICAL INTERPRETATION
POPULATIONS

IN

WILDLIFE

In most systems, the duration of detectable antibody following infection is not known. While positive reactions for
one antibody class (i.e., IgM) can be taken as evidence of
active or recent infection, it is not possible to infer timing of
infection from more commonly detected antibody classes
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(e.g., IgG). Repeated infection may be necessary to induce an
antibody response in some animals (Turmelle et al. 2010b),
and antibodies may persist from weeks to years, depending
on the host–pathogen system and individual variation (Aubert 1992). Importantly, the loss of detectable circulating
antibody does not necessarily represent a loss of immunity
with respect to subsequent pathogen infection (e.g., memory
lymphocytes). Rather, the animal may be primed immunologically to respond to re-infection, or mechanisms such as
cell-mediated immunity may also play a significant role in
infection resistance. It is typically impossible to know the
exposure histories of wild free-ranging animals, particularly
during cross sectional studies, and extremely challenging to
differentiate seronegative animals that were previously
seropositive from animals that have never encountered the
pathogen under study (i.e., are truly naı̈ve) (Table 1).
With age-structured sampling of mammalian wildlife,
maternally-derived antibody (MDAb) may be identified in
nursing or recently weaned young, but the function of MDAb
in most wildlife host-pathogen systems has not been wellcharacterized (Boulinier and Staszewski 2008). The presence
of MDAb can also interfere with individual immune responses
and can compromise the response to vaccination in offspring
(Xiang and Ertl 1992; Muller et al. 2001; Siegrist 2003). Evaluating the proportion of antibody-positive dams is necessary
for interpreting proportional antibody prevalence among
offspring in a social group or population, as the antibody titer
of the dam may impact the probability of transfer to, and the
level of MDAb in, respective offspring (Muller et al. 2002;
Boulinier and Staszewski 2008; Kallio et al. 2010). MDAb often
wane in juveniles around the time of weaning (Muller et al.
2002; Plowright et al. 2008), yet may be detected for a much
longer period of time using antibody-binding compared to
VNT assays (Muller et al. 2005). The effects of MDAb may vary
across and within host-pathogen systems, and few have been
adequately studied. Susceptibility to infection is presumed to
be high among offspring nursing from seronegative dams and,
where breeding is seasonal, the infection of offspring that are
naı̈ve or have waning MDAb may modulate seasonal pulses of
infection or disease outbreaks (Fouchet et al. 2007; Kallio et al.
2010; George et al. 2011; Plowright et al. 2011). Age-structured
serological studies have great potential for providing highly
informative insights for disease modeling (Heisey et al. 2006)
and disease management strategies (Farrington et al. 2001),
although timing of sampling intervals and proper cohort
representation are key considerations.
Despite substantial variation in the longevity of wildlife, the immune response to repeated pathogen infection in
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long-lived hosts has received little attention. For example,
humoral immune responses may be less important following repeated infection of bats with RABV (Turmelle
et al. 2010b), perhaps due to an increasing role of cellmediated defenses (Moore et al. 2006; Horowitz et al.
2010), potentially complicating a reliance on antibody
prevalence data for dynamic disease models in some hostpathogen systems. Certainly, expanding immunological
surveillance among wildlife to include different measures of
immunity holds exciting promise for modeling the perpetuation and emergence of infectious diseases in wildlife
(Graham et al. 2007).
Beyond initial decisions about which specific serological
test will be employed for a study, sample size and sampling
strategy must be carefully considered. Strategies might include capture of free-ranging animals or capture within a
roost, shelter, nest or burrow. Capture of refuging animals
may bias collection of sick or moribund animals which may
be more likely to be infected and seropositive. Comparison of
studies investigating RABV NAb seroprevalence in populations of bats suggests different NAb seroprevalence in bats
captured while roosting versus those in flight (Constantine
et al. 1968; Steece and Altenbach 1989; Turmelle et al. 2010a).
Furthermore, individual immunological response to infection among wildlife populations may vary due to host or
environmental factors (Bouma et al. 2010; Graham et al.
2010; Hawley and Altizer 2011). All studies must consider
that age and social structures of populations can vary in space
and time, potentially leading to variation in the types of
individuals sampled and estimates of antibody prevalence.

CONCLUSIONS
As new diagnostic techniques develop in the study of
wildlife disease, the challenges of interpretation of results
from all systems are increasing. When properly employed,
serological data can be very powerful for inference and
modeling of infectious disease dynamics in wildlife, but the
limitations must also be acknowledged. Development of
conceptual and mathematical models prior to field sampling, greater consideration of pathogenesis and age
structure in the population infection process, investment in
longitudinal studies whenever possible and standardized
sample collection, storage and testing protocols can ensure
that reliable and meaningful data are obtained for modeling
applications to effectively characterize, and evaluate intervention strategies for, wildlife disease systems.
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APPENDIX
Table 3.

Understanding Serological Assays.

Antibodies raised by individuals against a range of infections can be detected in sera in a variety of ways. Below is a short summary of
what can be detected, which typical assays measure this and the type of results.
Antigen-binding assays and their results
Antigen-binding assays measure the attachment of antibodies to pathogen
proteins which have been attached to a surface (e.g., bead, slide, plate)
(Fig. 1i). Once bound (Fig. 1ii), antibody is subsequently detected
using anti-antibody proteins (Fig. 1iii), often conjugated to an enzyme
that fluoresces for detection. Often the serum is diluted prior to
testing.

Schematic of antigen-binding assays
1. Western blots (WB) give qualitative results, based on the presence or
absence of antibody-antigen binding, detected by electrophoresis and
compared to positive and negative controls (Fig. 2). Occasionally
semi-quantitative results are given depending on the strength of the
band.

The presence of anti-Ebolavirus antibody (sample number
49) in a serum sample binding to antigen is detected using
electrophoresis in a western blot test
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continued

2. Immunofluorescence tests (IFAT) give qualitative depending on
the presence of antibody–antigen binding (Fig. 3) at serial
dilutions, and can be used to give quantitative results depending
on which dilution(s) the antibodies were detectable.

The presence of anti-antigen antibody in a serum sample detected
by an immunofluorescence test
3. Enzyme-linked immunosorbent assays (ELISA, EIA) are by default
quantitative. A seropositive result is defined by the strength of
color or fluorescence change, indicating the strength of signal and
the amount of binding (Fig. 4), and a threshold is used to decide if
it should be classified as positive, in order for qualitative results to
be reported. A competitive ELISA is a variation where antigen and
antibody are incubated together and conjugated antibody binds
unbound antigen, thus a reduction in strength of signal is used.

The presence of fluorescence due to increasing antibody–antigen
binding in an ELISA test in this schematic

Antibody-function assays and their results
Antibody-function assays measure the actions of antibodies for a specific pathway or function. These tests may be used to ‘‘type’’ or
‘‘characterize’’ the history of infection (e.g., influenza), or as an indirect measure of antibody levels. Sera may be serially diluted.
1. Hemagglutination inhibition and complement fixation assays give
qualitative results, based on the presence or absence of
hemagglutination, hemagglutination inhibition, or complement
fixation, and quantitative results by serially diluting the sera.
The presence of hemagglutination, the agglutination of
erythrocytes (Fig. 5a), shown in this 96-well plate (Fig 5b),
demonstrates viral particles are binding to the surfaces of
erythrocytes. Antibody in a serum sample would prevent this
and quantitative results can be determined by finding the
cut-off at which agglutination inhibition ceases.

The presence of hemagglutination, the clustering of red blood
cells, shown schematically (a) and in this 96-well plate (b).
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2. Virus or serum neutralisation tests (VNT/SNT), including
those using live or recombinant (e.g., pseudotyped)
viruses, measure the capacity of antibody to block a
function of the infection, such as cell entry. In such assays serial dilutions of sera are incubated with a standardized ‘‘amount’’ of virus, which are then cultured
with cells, in eggs, or historically animals. The results are
analyzed to determine at which serum dilution a proportion (typically 50% or 100%) of the virus is neutralized. The results are quantitative due to the presence
of antibody–antigen binding being detected by fluorescence or reduction in virus induced plaque formation in
cells at specific dilutions (Fig. 6a, b), and/or qualitative
based on the presence of antibody-antigen binding, or
determined by a cut-off value. Neutralization at lower
dilutions (e.g., less than 1:10) is sometimes considered
non-specific.

The reduction of plaque forming units is shown across at lower
serum dilutions (i.e., 1:10) (a) and the presence of non-neutralized virus is detected by fluorescence in a virus neutralization test
(b).The presence or absence of virus at different serum dilutions
is used to determine antibody titers and a threshold at which
neutralization activity occurs.
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